|
Back to Home » November 2018 News » AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy |
AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy |
November 01, 2018
NORTH CHICAGO, Ill., Nov. 1, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the European Commission (EC) has approved the type-II variation application for VENCLYXTO® (venetoclax) in combination with rituximab for the...
Source URL: https://www.prnewswire.com:443/news-releases/abbvie-receives-european-commission-approval-of-venclyxto-venetoclax-plus-rituximab-for-the-treatment-of-patients-with-chronic-lymphocytic-leukemia-who-have-received-at-least-one-prior-therapy-300741883.html
|
|
|
|
